Company Presentation

Cellis is developing Macrophage Drug Conjugates (MDCs) which is a breakthrough, new class of therapy for solid tumors. Cellis uses allogeneic macrophages conjugated with therapeutic medications for treatment of several solid tumors. Our current focus is on glioblastoma, ovarian and pancreatic cancer. Current preclinical results show elimination of tumors or significant tumor shrinkage. Preparation is underway to progress our technology to the first in human clinical trials.